Live Breaking News & Updates on Pegylated interferon alpha

Stay informed with the latest breaking news from Pegylated interferon alpha on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Pegylated interferon alpha and stay connected to the pulse of your community

Potential Combination Therapy Approaches with Ruxolitinib in Myelofibrosis

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

Myeloproliferative-neoplasms , Combination-therapy-approaches , Myelofibrosis , Novel-combination-therapy , Ruxolitinib , Jak2-inhibitor , Pelabresib , Pegylated-interferon-alpha , Navitoclax , Bcl-xl , Bcl-2

Zydus Cadila Virafin Covid medicine approved treating coronavirus in adults

URL copied
Image Source : AP
A health worker prepares to administer the COVAXIN vaccine for COVID-19 to a man at an indoor stadium. (Representational image)
Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, 'Virafin'Â for treating moderate COVID-19 infection in adults.
Earlier, Zydus Cadila announced that its Phase III clinical trials with Pegylated Interferon Alpha 2b, PegiHep has shown promising results in treating Covid-19.
In what could be a breakthrough in the disease management of Covid, the interim results indicate that PegIFN when administered early on, could help patients recover faster and avoid much of the complications seen in the advanced stages of the disease.

India , Zydus-cadila , Image-source , Controller-general , Pegylated-interferon , Pegylated-interferon-alpha , Interferon-alpha , Virafin-covid-medicine , Ydus-cadila-covid-medicine , Lpha-2b , Ovid-19

Zydus Cadila seeks DCGI approval for use of PegIFN in treating COVID-19

Zydus Cadila announced that its Phase III clinical trials with Pegylated Interferon Alpha 2b, PegiHepTM has shown promising results in treating COVID-19. In what could be a breakthrough in the disease management of COVID-19, the interim results indicate that PegIFN when administered early on, could help patients recover faster and avoiding much of the complications seen in the advanced stages of the disease. PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents. The treatment regimen would be less cumbersome and more affordable for patients as Pegylated Interferon Alpha 2b, is a single dose regimen.
It would also ensure better compliance. PegIFN has very well-established safety with multiple doses in chronic hepatitis B and C patients since many years. Patients on Pegylated Interferon Alpha 2b during the trial also showed lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19. The findings are in line with recently reported importance of early IFN treatment given in combination with steroids in the treatment of COVID-19 (Lu et al, Signal Transduction and Targeted Therapy (2021) 6:107, a Nature publication. With these positive results, the Company has applied for an approval for additional indication with the DCGI for the use of PegIFN in the treatment of COVID 19.

Zydus-cadila , Pegylated-interferon-alpha , Signal-transduction , Targeted-therapy , Capital-market , Antiviral-drugs , Drugs , Medical-specialties , Cytokines , Medicine , Pegylated-interferon

Zydus Cadila seeks DCGI nod for use of PegiHep in Covid-19 treatment

Zydus Cadila seeks DCGI nod for use of PegiHep in Covid-19 treatment
April 05, 2021
Phase-3 clinical trials showed promising results in treating Covid-19
In what could be termed a major breakthrough in the disease management of Covid-19, drug major Cadila Healthcare Limited (Zydus Cadila) has said that initial Phase-III clinical trials of Pegylated Interferon Alpha 2b, PegiHep, showed promising results in the treatment of the novel coronavirus.
The interim results indicate that PegIFN, when administered early on, could help patients recover faster, avoiding many of the complications seen in the advanced stages of the disease.
The company has sought the Drugs Controller General of India’s approval for the use of Pegylated Interferon alpha-2b in treating Covid-19 in India. Pegylated Interferon alpha-2b, or PegiHepTM, is an approved drug in India and is being re-purposed for the treatment of Covid-19.

India , Mexico , Zydus-cadila , Sharvil-patel , Cadila-healthcare-ltd , Cadila-healthcare-limited-zydus , Cadila-healthcare-limited , Pegylated-interferon-alpha , Drugs-controller-general , Pegylated-interferon , Interferon-alpha , Managing-director

Zydus Cadila DCGI nod hepatitis drug COVID19 treatment use

URL copied
Zydus Cadila seeks DCGI nod for use of hepatitis drug for COVID-19 treatment
Drug firm Zydus Cadila on Monday said it has sought approval from the domestic drug regulator Drugs Controller General of India (DCGI) for the additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating COVID-19. Phase-III clinical trials with Pegylated Interferon Alpha 2b, which the company sells under the brand name 'PegiHep' has shown promising results in treating COVID-19, Zydus Cadila said in a statement.
The interim results indicate that the drug when administered early on, could help patients recover faster and avoid much of the complications seen in the advanced stages of the disease, it added.

Mexico , United-states , India , Zydus-cadila , Sharvil-patel , Zydus-group , Drug-administration , Image-source , Drugs-controller-general , Pegylated-interferon , Pegylated-interferon-alpha , Indian-innovation

Zydus' COVID-19 drug shows promise in Phase 3 trials; seeks DCGI nod

Zydus' COVID-19 drug shows promise in Phase 3 trials; seeks DCGI nod
Over 91.15% of patients treated with PegIFN were found to be RT PCR negative by day 7 as compared to 78.90 per cent on the 'standard of care' arm; PegIFN reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate COVID-19 patients
BusinessToday.In | April 5, 2021 | Updated 12:51 IST
Interim results show PegIFN could help patients recover faster, avoiding complications seen in the advanced stages
Zydus Cadila announced on Monday, April 5 that it has sought approval from drug regulator DCGI (Drugs Controller General of India) for its drug Pegylated Interferon Alpha 2b (PegIFN) to be used in the treatment of COVID-19 patients. The domestic pharma company has applied for an approval for additional indication with DCGI for the use of PegIFN, announcing that its phase-III clinical trials with the drug have manifested promising results in treating coronavirus patients.

Mexico , India , Zydus-cadila , Sharvil-patel , Cadila-healthcare-ltd , Drugs-controller-general , Pegylated-interferon-alpha , Interferon-alpha , Pegylated-interferon , Indian-innovation , Managing-director , Zydus-cadila-covid-19-drug

Stock in news: Reliance, Future Retail, Dalmia Bharat, Vedanta, SBI Cards

Stock in news: Reliance, Future Retail, Dalmia Bharat, Vedanta, SBI Cards
Shares of Reliance, SBI, Future Retail, Dalmia Bharat, Vedanta, SBI Cards will be in focus in Monday's trading session
BusinessToday.In | April 5, 2021 | Updated 09:54 IST
Stocks to watch today: Reliance, SBI, Future Retail, Dalmia Bharat, Vedanta, SBI Cards
The domestic bourses, Sensex and Nifty, are expected to open lower on Monday, tracking negative trading at Nifty futures on the Singapore Exchange. Among the individual stocks, shares of Reliance Industries, State Bank of India, Future Retail, Dalmia Bharat, Vedanta, SBI Cards, Britannia Industries and Adani Enterprises will be in focus in Monday's trading session.

Mumbai , Maharashtra , India , Singapore , Zydus-cadila , Dalmia-bharat , Kiratpur-ner-chowk-expressway-ltd , Infrastructure-leasing-financial-services-ltd , Il-fs-securities-services , Reliance-industries-limited , Britannia-industries , Payment-services

Zydus Cadila seeks DCGI nod for use of hepatitis drug for Covid-19 treatment | India News

Representative image (AFP)
NEW DELHI: Drug firm Zydus Cadila on Monday said it has sought approval from the domestic drug regulator drugs controller general of India (DCGI) for additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating Covid-19.
Phase-III clinical trials with Pegylated Interferon Alpha 2b, which company sells under the brand name 'PegiHep' has shown promising results in treating Covid-19, Zydus Cadila said in a statement.
The interim results indicate that the drug when administered early on, could help patients recover faster and avoid much of the complications seen in the advanced stages of the disease, it added.

Mexico , United-states , India , Zydus-cadila , Sharvil-patel , Zydus-group , Pegylated-interferon , Pegylated-interferon-alpha , Indian-innovation , Cadila-healthcare , India-news , India-news-today

Zydus seeks DCGI approval for using PegIFN in COVID-19 treatment

91.15% of patients treated with PegIFN were RT PCR negative by day 7 as compared to
78.90% on the standard of care (SOC) arm

Mexico , Pegihep-peg , Zydus-cadila , Sharvil-patel , Cadila-healthcare-ltd , Pegylated-interferon-alpha , Signal-transduction , Targeted-therapy , Managing-director , Pegylated-interferon , Indian-innovation , Dcgi

Welcome To IANS Live - NATION - Promising results with Pegylated Interferon alpha-2b in Covid show higher clinical improvement

In what could be a breakthrough in the disease management of Covid, the interim results indicate that PegIFN when administered early on, could help patients recover faster and avoid much of the complications seen in the advanced stages of the disease. Peg

India , New-delhi , Delhi , Zydus-cadila , Twitter , News-service , India-private , Pegylated-interferon , Pegylated-interferon-alpha , All-rights , Patients , Interferon